本港疫苗股隨外圍急挫20%-27% 默克研發新冠口服藥有助降低患者一半住院和死亡率
美國藥廠默克(MRK.US)公佈其研發新冠口服藥Molnupiravir能使確診者的住院和死亡率減半,並將向美國等其他國家申請緊急授權使用,刺激上週五股價急漲8.4%創近五年最大升幅兼爲最強藍籌。相反,其他疫苗股遭拋售,尤其是Moderna(MRNA.US)、Novavax(NVAX.US)及CureVac(CVAC.US)急挫近11.5%-15%,INO、BioNTech(BNTX.US)及Vaxart(VXRT)也依次跌6.4%-9.7%。
本港上市疫苗股也難逃急挫厄運,尤其是復星醫藥(02196.HK)、康希諾生物-B(06185.HK)、開拓藥業-B(09939.HK)及騰盛博藥-B(02137.HK)急挫20%-27%,分別低見31.6元、193.8元、38.5元及27.95元,創半年、近九個月、近半年低及兩個月低。
此外,藍籌藥明生物(02269.HK)一舉失守50天、20天、10天及100天線(119.9-122.9元),最低見115元,現報115.5元,回吐8.7%,爲最傷藍籌。嘉和生物-B(06998.HK)重失百天線(14.05元),最低見11.74元,現報11.9元,急吐近17%。諾誠健華-B(09969.HK)跌破牛熊線、10天及20天線(19.08-20.75元),低見18.04元創半年低,現報18.08元,下挫14%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.